Prevention of Preeclampsia-associated preterm births
Prevention of Preeclampsia-associated preterm births
批准号:
8780971
负责人:
SHEAU-YU Teddy HSU
金额:
$22.5万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-08-01 至 2016-01-31
关键词:
AffectAgonistAngiogenic FactorAnimal ModelAnimalsAntihypertensive AgentsBirthBlood CirculationBlood VesselsCardiovascular systemCaringCessation of lifeDefectDevelopmentDiseaseDrug KineticsEdemaEndocrine systemEquilibriumExhibitsFaceFetal Growth RetardationFetusGestational AgeGoalsHormonal ChangeHormonesHumanHypertensionInvestigationInvestigational DrugsLeadLifeMaternal-Fetal ExchangeMedicalModelingMorbidity - disease rateNeonatalNitric Oxide SynthaseOrgan failurePatientsPeripheral ResistancePhasePlacentaPlayPre-EclampsiaPregnancyPremature BirthPremature InfantPreventionProteinuriaRAMP1RattusReceptor SignalingRegulationRodent ModelRoleSeizuresSmall Business Innovation Research GrantStagingSymptomsTestingTherapeuticTissuesToxicologyUnited StatesUnited States Food and Drug AdministrationVascular Diseasesadrenomedullinanalogbasecostdesigndrug candidateendothelial dysfunctionfetalfetal bloodglomerular functionimprovedin vivoinhibitor/antagonistmeetingsmortalitynovelnovel therapeuticspre-clinicalpregnantpreventprotective effectpublic health relevancereceptor
中文摘要
描述(申请人提供):先兆子痫是一种妊娠特有的高血压疾病,影响5-8%的妊娠。这种疾病可能导致多器官衰竭、癫痫发作和产妇死亡。在美国,先兆子痫也是导致早产的高达20%的原因。尽管更好的新生儿护理提高了早产儿存活的可能性,但许多人面临着更高的死亡率和严重的长期发病率。医学专家一致认为,预防婴儿出现与子痫前期相关的不良反应的最好方法是推迟早产。不幸的是,在大多数先兆子痫患者中,目前的治疗方法在推迟分娩几天以上方面无效。尽管子痫前期的病因尚不清楚,但子痫前期已被认为是一种两阶段疾病,涉及母胎界面缺陷和母体血管功能障碍。这些缺陷可能导致全身性内皮功能障碍。结果,母婴血液循环受到限制,导致高血压、蛋白尿和胎儿生长迟缓。最近的发现表明,一组血管受体,CLR/RAMP受体,在妊娠期间胎盘组织的发育和血管紧张素的调节中起着至关重要的作用。重要的是,已有研究表明,阻断CLR/RAMP受体信号转导会在动物模型中导致先兆子痫样症状,而这些CLR/RAMP受体激动剂可以抑制在妊娠晚期使用一氧化氮合酶抑制剂预处理的动物的先兆子痫样症状。因此,CLR/RAMP受体信号通路的药理激活有望成为治疗先兆子痫患者高血压、蛋白尿和胎儿生长迟缓、降低早产可能性的有效途径。我们的目标是研究一组新型CLR/RAMP受体激动剂的保护作用,这些激动剂在体内具有强大的抗高血压作用,在先兆子痫大鼠模型中。这些新型候选药物的有效性的成功展示将验证我们的先导化合物的进一步开发,并促进第二阶段SBIR研究中GLP药代动力学和毒理学研究的设计。
英文摘要
DESCRIPTION (provided by applicant): Preeclampsia is a pregnancy-specific, hypertensive disorder that affects 5-8% of pregnancies. This disorder can lead to multi-organ failure, seizure, and maternal death. Preeclampsia is also responsible for as many as 20% of premature births in the United States. Although better neonatal care has improved the likelihood of preterm babies surviving, many face increased mortality and serious long-term morbidities. Medical experts agree that the best approach to prevent adverse preeclampsia-associated effects in babies is to delay premature birth. Unfortunately, current treatments are ineffective at delaying labor by more than a couple of days in the majority of preeclampsia patients. Although the cause of preeclampsia remains unclear, preeclampsia has been proposed to be a two-stage disease, which involves defects at the maternal-fetal interface as well as maternal vascular dysfunction. These defects could lead to systemic endothelial dysfunction. As a result, maternal-fetal blood circulation is restricted, leading to high blood pressure, proteinuria, and fetal growt retardation. Recent discoveries have shown that a group of vascular receptors, CLR/RAMP receptors, play crucial roles in the development of feto- placental tissues and vasotone regulation during pregnancy. Importantly, it has been shown that blocking CLR/RAMP receptor signaling leads to preeclampsia-like symptoms in animal models, and those agonists for CLR/RAMP receptors can dampen preeclampsia-like symptoms in animals that have been pretreated with a nitric-oxide-synthase inhibitor during late pregnancy. Therefore, pharmacological activation of CLR/RAMP receptor signaling could be a promising approach to treat hypertension, proteinuria, and fetal growth retardation in preeclampsia patients, and to reduce the likelihood of preterm birth. Our goal is to investigate the protective effects of a grou of novel CLR/RAMP receptor agonists, which have potent anti-hypertensive effects in vivo, in a preeclamptic rat model. Successful demonstration of the efficacy of these novel drug candidates would validate our lead compounds for further development, and facilitate the design of GLP pharmacokinetic and toxicology studies in the Phase 2 SBIR investigation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A therapy for improving diabetic ulcer healing
-
批准号:10820107
-
项目类别:
-
资助金额:$33.53万
-
财政年份:2023
-
负责人:SHEAU-YU Teddy HSU
-
依托单位:
Novel Therapeutics for Endothelial Dysfunction
-
批准号:9253486
-
项目类别:
-
资助金额:$29.04万
-
财政年份:2017
-
负责人:SHEAU-YU Teddy HSU
-
依托单位:
Developing Novel Therapies for Treating Breast-Cancer-Related Lymphedema
-
批准号:8647758
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2014
-
负责人:SHEAU-YU Teddy HSU
-
依托单位:
Role of RAMPs in Intermedin Signaling
-
批准号:7771528
-
项目类别:
-
资助金额:$0.16万
-
财政年份:2006
-
负责人:SHEAU-YU Teddy HSU
-
依托单位:
Role of RAMPs in Intermedin Signaling
-
批准号:7437340
-
项目类别:
-
资助金额:$27.65万
-
财政年份:2006
-
负责人:SHEAU-YU Teddy HSU
-
依托单位:
Role of RAMPs in Intermedin Signaling
-
批准号:7147883
-
项目类别:
-
资助金额:$27.74万
-
财政年份:2006
-
负责人:SHEAU-YU Teddy HSU
-
依托单位:
Role of RAMPs in Intermedin Signaling
-
批准号:7258366
-
项目类别:
-
资助金额:$28.21万
-
财政年份:2006
-
负责人:SHEAU-YU Teddy HSU
-
依托单位:
Role of RAMPs in Intermedin Signaling
-
批准号:7636767
-
项目类别:
-
资助金额:$27.62万
-
财政年份:2006
-
负责人:SHEAU-YU Teddy HSU
-
依托单位:
Identification of Relaxin Receptor Antagonists
-
批准号:6947202
-
项目类别:
-
资助金额:$21.54万
-
财政年份:2004
-
负责人:SHEAU-YU Teddy HSU
-
依托单位:
Identification of Relaxin Receptor Antagonists
-
批准号:6815923
-
项目类别:
-
资助金额:$18.92万
-
财政年份:2004
-
负责人:SHEAU-YU Teddy HSU
-
依托单位:
PHYSIOLOGY OF RELAXIN-INSULIN-LIKE FACTORS
-
批准号:6261321
-
项目类别:
-
资助金额:$7.85万
-
财政年份:2001
-
负责人:SHEAU-YU Teddy HSU
-
依托单位:
PHYSIOLOGY OF RELAXIN-INSULIN-LIKE FACTORS
-
批准号:6530545
-
项目类别:
-
资助金额:$7.85万
-
财政年份:2001
-
负责人:SHEAU-YU Teddy HSU
-
依托单位:
国内基金
海外基金
Agonist-GPR119-Gs复合物的结构生物学研究
-
批准号:32000851
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:乔安娜
-
依托单位: